Transcriptional profile and immune infiltration in colorectal cancer reveal the significance of inducible T‐cell costimulator as a crucial immune checkpoint molecule

Abstract

AbstractBackgroundEmergence of novel immuno‐therapeutics has shown promising improvement in the clinical outcome of colorectal cancer (CRC).ObjectiveTo identify robust immune checkpoints based on expression and immune infiltration profiles of clinical CRC samples.MethodsOne dataset from The Cancer Genome Atlas database and two from Gene Expression Omnibus were independently employed for the analysis. Genes associated with overall survival were identified, and distribution of each immune checkpoint with respect to different clinical features was determined to explore key immune checkpoints. Multiple staining methods were used to verify the correlation between key immune checkpoint ICOS and clinical pathological features. Differentially expressed mRNA and long non‐coding RNA (lncRNA) were then detected for gene set enrichment analysis and gene set variation analysis to investigate the differentially enriched biological processes between low‐ and high‐expression groups. Significant immune‐related mRNAs and lncRNA were subjected to competing endogenous RNA (ceRNA) network analysis. Correlation of inducible T‐cell costimulator (ICOS) and top 10 genes in ceRNA network were further considered for validation.ResultsICOS was identified from 14 immune checkpoints as the most highly correlated gene with survival and clinical features in CRC. The expression of ICOS protein in the poorly differentiated group was lower than that in the moderately differentiated group, and the expression in different pathological stages was significant. In addition, the expressions of ICOS were negatively correlated with Ki67. A conspicuous number of immune‐related pathways were enriched in differentially expressed genes in the ICOS high‐ and low‐expression groups. Integration with immune infiltration data revealed a multitude of differentially expressed immune‐related genes enriched for ceRNA network. Furthermore, expression of top 10 genes investigated from ceRNA network showed high correlation with ICOS.ConclusionICOS might serve as a robust immune checkpoint for prognosis with several genes being potential targets of ICOS‐directed immunotherapy in CRC.